Sept. 29, 2023

22 - Chronicling Healthcare’s End Times: Rite Aid, HealthComp, Pharma, FTC & Government Shutdown

22 - Chronicling Healthcare’s End Times: Rite Aid, HealthComp, Pharma, FTC & Government Shutdown

In Episode 22 of Health:Further, we'll be covering a range of topics, including:

Rite Aid plans to shutter stores in bankruptcy, and private equity-owned healthcare companies are merging in a $3 billion deal. The broken business model in the...

In Episode 22 of Health:Further, we'll be covering a range of topics, including:

Rite Aid plans to shutter stores in bankruptcy, and private equity-owned healthcare companies are merging in a $3 billion deal. The broken business model in the pharmaceutical industry hinders the development of new antibiotics, and a shortage of a life-saving cancer therapy persists. Elevance and Blue Cross Louisiana halt a proposed $2.5 billion deal. The FTC sues a private equity-backed anesthesia provider and Amazon for alleged monopolistic practices in the online marketplace.

And many more! Please check out our Episode Resources below:


------🔎RESOURCES🔎

Rite Aid Plans to Shut Down Hundreds of Stores in Bankruptcy (WSJ)

Private Equity-Owned Healthcare Companies to Join in $3 Billion Merger (WSJ)

The World Needs New Antibiotics, but the Business Model Is Broken (WSJ)

This Cancer Therapy is Lifesaving, but There Isn’t Enough of It (WSJ)

Elevance, Blue Cross Louisiana halt $2.5B proposed deal (Modern Healthcare)

FTC Sues Large Private-Equity-Backed Anesthesia Provider (Modern Healthcare)

FTC Sues Amazon, Alleging Illegal Online-Marketplace Monopoly (WSJ)

Amazon’s Thin Profit Margins and Growing Competition Undercuts the FTC’s Case (WSJ)

Google Trial Spills Details on Search Engine’s Deals With Apple, & Samsung (WSJ)

How a government shutdown affects Medicare, Medicaid benefits (Washington Post)


------🔔SIGN UP FOR EPISODE NOTIFICATIONS🔔

https://www.podpage.com/healthfurther/


------📱FOLLOW HEALTH:FURTHER SOCIALS📱

INSTAGRAM // https://www.instagram.com/healthfurther/

TWITTER //